Observational studyBMC gastroenterology2026
Differential impacts of Helicobacter pylori antibody typing on gastric secretory function: a cross-sectional study based on serum biomarkers.
Observational study in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Component-specific effects of PMFrontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAlthough gastric secretory dysfunction is common in H.pylori-associated gastropathy, the precise mechanisms underlying these functional alterations across different H.pylori antibody subtypes remain incompletely elucidated. This cross-sectional clinical observational study aimed to systematically investigate the associations between specific H.pylori antibody subtype infection status and multiple gastric functional parameters, thereby elucidating potential differences in their impact on gastric secretory function.
methodsA total of 2,618 patients were included in this analysis. Serum levels of pepsinogen I (PGI), pepsinogen II (PGII), the PGI/PGII ratio (PGR), gastrin-17 (G-17), and H.pylori antibody subtypes were measured. A cross-sectional study design was employed to analyze baseline characteristics and serological data.
resultsCompared to the H.pylori-positive group, the H.pylori-negative group demonstrated significantly higher PGI (P = 0.020) and PGR (P < 0.001) levels, while PGII levels were markedly lower (P < 0.001). In the H.pylori subtype analysis, both H.pylori(I) and H.pylori(II) groups exhibited elevated PGII levels compared to the negative group, whereas PGR showed a progressive decreasing trend: H.pylori(I) < H.pylori(II) < H.pylori(-) (P < 0.001). Furthermore, both infected groups had significantly higher G-17 levels than the H.pylori(-) group (all P < 0.001). Males showed higher PGI levels in the infected groups, while in the H.pylori(-) group, multiple parameters (PGII, PGI, G-17) were elevated in males compared to females (P < 0.05). Patients aged ≤ 60 years had lower PGI and PGII levels but higher PGR (P < 0.05). Correlation analysis further indicated that G-17 was positively correlated with PGII and negatively correlated with PGR (P < 0.05).
conclusionsH.pylori infection characteristically alters gastric functional serum markers in a virulence-dependent manner. These patterns biologically reflect the continuous pathological process from gastric mucosal inflammation to atrophy. Our findings underscore the clinical relevance of integrating H.pylori subtyping with gastric function assessment in gastric cancer risk screening, providing a novel perspective for the precise identification of high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.